The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress

Multiple Myeloma MORE >>

Adding thalidomide to induction and maintenance therapy in stem cell transplant-eligible, newly diagnosed patients with multiple myeloma improved event-free survival and progression-free survival compared with standard chemotherapy drugs and interferon alfa, according to a long-term follow-up analysis from a phase III open-label randomized trial.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.